Darden Restaurants Inc. (NYSE: DRI) is scheduled to report first quarter 2020 earnings results on Thursday, September 19, before the market opens. Revenues are expected to increase 3.8% year-over-year to $2.14 billion and earnings are expected to grow 1.5% to $1.36 per share.
The company’s topline performance is expected to be driven by strength in the Olive Garden, LongHorn Steakhouse and Fine Dining segments which have delivered healthy sales increases. The growth in same-restaurant sales, led by Olive Garden and LongHorn Steakhouse, is expected to continue during the first quarter.
The restaurant chain, however, faces challenges from weak customer traffic, particularly in Olive Garden, and the company’s plans on driving this metric will be worth watching. Another cause of concern is higher costs which are likely to pressure margins.
Darden has been investing in remodels and culinary innovation at its Olive Garden and LongHorn divisions. The Brand Renaissance plan and To Go business are expected to drive momentum at Olive Garden while the menu innovation could help in driving comp sales growth at LongHorn.
In the fourth quarter of 2019, Darden beat earnings estimates while sales fell short of forecasts. Sales grew 4.5% to $2.23 billion while adjusted EPS jumped 27% to $1.76. Blended same-restaurant sales rose 1.6%.
For fiscal-year 2020, Darden expects total sales growth of 5.3-6.3%, including approx. 2% growth related to the 53rd week. Same-restaurant sales is expected to grow 1-2%. Diluted EPS from continuing operations is expected to be $6.30-6.45.
Shares of Darden have gained 29% so far this year and 10% in the past one month. The stock has an average price target of $127.92.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated